Article Sidebar
Published:
Aug 21, 2022Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Effect of a combination of oxaliplatin and fluoropyrimidine derivative molecule S-1 on expression levels of IL-9 and CysLTR-1 in a rat model of colon cancer
Abstract
Purpose: To investigate the effect of a combination of oxaliplatin and fluoropyrimidine derivative molecule S-1 on the expression levels of IL-9 and CysLTR-1 in rats with colon cancer.
Methods: One hundred and eighty healthy Spraque Dawley rats were randomly assigned to groups A (healthy control), B (model), and C (treatment) with 60 rats in each group. Western blotting was used to determine contents of CysLTR-1 and related pathway proteins, while the levels of IL-9 and IFN-γ were evaluated by enzyme-linked immunosorbent assay (ELISA). Cell Counting Kit-8 (CCK-8) was used to determine cell proliferation, while cell apoptosis was assessed using flow cytometry.
Results: Tumor volume was larger and tumor diameter was longer in group B than in group C (p < 0.05). The expression levels of CysLTR-1, LTD4, β-catenin, COX-2, IL-9 and IFN-γ were significantly up-regulated in groups B and C, relative to group A (p < 0.05). Cell proliferation was also significantly faster in groups B and C than in group A, while apoptotic rate was lower (p < 0.05).
Conclusion: Combined use of OX and S-1 inhibits CysLTR-1 expression level in colon cancer rats. Furthermore, it down-regulates IL-9 expression, thereby inhibiting the proliferation and apoptosis of tumor cells. Therefore, the combination treatment has potentials for development as a therapeutic strategy for the management of colon cancer.
Keywords: Oxaliplatin; Fluoropyrimidine derivative molecule; Colon cancer; CysLTR-1
